Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Head-to-head evidence comparison — which supplement is right for you?
Saccharomyces Boulardii wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
8 of 15 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
13 of 15 studies with measurable effects showed benefit.
Top outcomes
500-2000mg daily for lipid effects; 50-500mg for general health
With food (reduces flush), Evening for lipid effects, Split doses for high amounts
Immediate-release niacin (nicotinic acid)
250-500mg (5-10 billion CFU) daily
With or without food, At least 2 hours away from antifungals
Capsules (lyophilized)
4-8 weeks
4-8 weeks
30-60 minutes after dose
During use
1-3 days
1-2 weeks
Niacin for primary and secondary prevention of cardiovascular events
The Cochrane database of systematic reviews (2017) · Meta analysis · n=39195
Participants randomised to niacin were more likely to discontinue treatment due to side effects than participants randomised to control group (RR 2.17, 95% CI 1.70 to 2.77; participants = 33,539; studies = 17; I2 = 77%; moderate-quality evidence).
Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials
Atherosclerosis (2025) · Meta analysis · n=145314
Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels.
A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Nature medicine (2024) · Meta analysis
Lastly, treatment with physiological levels of 4PY, but not its structural isomer 2PY, induced expression of VCAM-1 and leukocyte adherence to vascular endothelium in mice.
Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis
Frontiers in cellular and infection microbiology (2025) · Meta analysis · n=5036
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut; a systematic review and meta-analysis of clinical outcomes
Gut microbes (2024) · Meta analysis · n=2871
This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
Based on multiple meta-analyses showing HDL increases. Higher doses increase discontinuation rates due to side effects (RR 2.17). Immediate-release forms have better lipid effects but more flushing.
Based on multiple meta-analyses showing 1.1-1.6 day reduction in diarrhea duration. Effect size appears to plateau at standard therapeutic doses. Limited data on doses above 20 billion CFU.
AI-estimated from published studies. Interpret as directional guidance.
Saccharomyces Boulardii has a higher evidence score (9/10 vs 9/10) and wins in 1 of 3 categories.
For reduce inflammation, Saccharomyces Boulardii has a higher relevance score (90 vs 85).
No known interactions between Niacin and Saccharomyces Boulardii have been documented in our database. However, always consult a healthcare provider before combining supplements.